Using second trimester ultrasound and maternal serum biomarker data to help detect congenital heart defects in pregnancies with positive triple-marker screening results.

Using second trimester ultrasound and maternal serum biomarker data to help detect congenital heart defects in pregnancies with positive triple-marker screening results. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Using second trimester ultrasound and maternal serum biomarker data to help detect congenital heart defects in pregnancies with positive triple-marker screening results. Abstract Text:

Congenital heart defects (CHDs) are the most common of all birth defects. For many newborns with a CHD, prenatal versus postnatal detection is associated with substantially decreased morbidity and mortality risks. Although technological advances in fetal echocardiography have led to an increased capacity to detect CHDs prenatally, pregnancies without an identified risk factor are not routinely screened. With the aim of identifying pregnancies at increased risk for CHDs, this study examined the relationship between CHDs and typically collected second trimester biomarker data collected on a large population-based sample of singleton pregnancies with one or more second trimester screen positive result for Down syndrome, trisomy 18 (T-18), Smith-Lemli-Opitz syndrome (SLOS), or a neural tube defect (NTD). Where possible, logistic models for cases and controls were built and potential referral models were tested among study subsamples with information on the presence or absence of CHDs reported pre- and perinatally. When considered in combination, screen positive for T-18, screen positive for SLOS, nuchal fold measurement > or = 5 mm, and/or having an adjusted hCG multiple of the median > or = the 95th centile detected 42.7% of all pregnancies with a CHD in the combined subsample (where co-occurrence with chromosomal defects was not considered) and detected 29.7% of all pregnancies with a CHD in the no-chromosomal defect subsample. A nuchal fold measurement > or = 5 mm detected 18.2% of those with a CHD in the Down syndrome subsample and an adjusted hCG multiple of the median (MoM) < or = 5th centile detected 92.9% of those with a CHD in the T-18 subsample.

Using second trimester ultrasound and maternal serum biomarker data to help detect congenital heart defects in pregnancies with positive triple-marker screening results. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Using second trimester ultrasound and maternal serum biomarker data to help detect congenital heart defects in pregnancies with positive triple-marker screening results. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: American journal of medical genetics. Part A

VOLUME: 146A

Page Numbers: 2455-67

Journal Abbreviation: Am. J. Med. Genet. A

ISSN: 1552-4833

DAY: 1

MONTH: Oct

YEAR: 2008

Using second trimester ultrasound and maternal serum biomarker data to help detect congenital heart defects in pregnancies with positive triple-marker screening results. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101235741

Using second trimester ultrasound and maternal serum biomarker data to help detect congenital heart defects in pregnancies with positive triple-marker screening results. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Using second trimester ultrasound and maternal serum biomarker data to help detect congenital heart defects in pregnancies with positive triple-marker screening results. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Using second trimester ultrasound and maternal serum biomarker data to help detect congenital heart defects in pregnancies with positive triple-marker screening results.

AFFILIATION: Genetic Disease Screening Program, California Department of Public Health, Richmond, CA 94804, USA. laura.jelliffe@cdph.ca.gov

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Am J Med Genet A

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Using second trimester ultrasound and maternal serum biomarker data to help detect congenital heart defects in pregnancies with positive triple-marker screening results Related Publications

• A novel helical double-layered cobalt(II)-organic framework with tetranuclear [Co4(mu3-OH)2] clusters linked by an unsymmetrical pyridylbenzoate ligand.
• Acute myocardial infarction secondary to left main coronary artery compression by pulmonary artery aneurysm in pulmonary arterial hypertension.
• An ergot alkaloid preparation (Hydergine) in the treatment of dementia: critical review of the clinical literature.
• Deafness-A Modern Approach to Its Treatment.
• Effect of Longitudinal Versus Transverse Electrode Placement on Torque Production by the Quadriceps Femoris Muscle during Neuromuscular Electrical Stimulation.
• Evaluation of Sex Differences of Fosamprenavir (With and Without Ritonavir) in HIV-Infected Men and Women.
• Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells.
• How to choose which examination to take and how to acknowledge certified nurses.
• Management of antiretroviral treatment-related complications.
• OTOLOGICAL DIAGNOSTIC CLINICS OF CALIFORNIA.
• Otological diagnostic clinics of California.
• Risk of myocardial infarction and nucleoside analogues.
• Sex differences in antiretroviral therapy toxicity: lactic acidosis, stavudine, and women.
• Significance of Isolated Positive IgM Serologic Results by Enzyme Immunoassay for Coccidioidomycosis.
• Ultrasound in ear, nose and throat disease.
• Urgent surgical decompression compared to methylprednisolone for the treatment of acute spinal cord injury: a randomized prospective study in beagle dogs.
• Using second trimester ultrasound and maternal serum biomarker data to help detect congenital heart defects in pregnancies with positive triple-marker screening results.